<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01819857</url>
  </required_header>
  <id_info>
    <org_study_id>RO4</org_study_id>
    <secondary_id>MUG4</secondary_id>
    <nct_id>NCT01819857</nct_id>
  </id_info>
  <brief_title>Droperidol and Cardiac Repolarization</brief_title>
  <official_title>The Influence of Droperidol on Cardiac Repolarization. A Double-blind, Ondansetron-controlled Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Gdansk</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Gdansk</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For many years droperidol has been used in prophylaxis and therapy of PONV. Information that
      it can provoke disorders of cardiac ventricular rhythm reduced its popularity. However those
      data didn't base on solid examinations confirming torsadogenic action of droperidol. It is
      known that droperidol prolongs time of repolarisation, but there wasn't any data confirming
      its impact on transmural dispersion of repolarisation. Only estimation both of those actions
      in one time allows to define for sure arrhythmogenic role of droperidol.

      The aim of this study was to answer the questions:

      6. Does droperidol make an significant prolongation of heart repolarisation, expressed as
      corrected QT interval?

        1. Does droperidol cause increase of transmural dispersion of repolarisation?

        2. Does possible torsadogenic acting of droperidol depend on dose of drug?

        3. Does ondansetron cause changes of electrical heart function, suggesting its
           possibilities to induce TdP tachycardia?

        4. What is torsadogenic potential of droperidol and ondansetron used in prophylaxis PONV in
           people not suffering from cardiovascular diseases?
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in QT interval value, QTc interval value and transmural dispersion of repolarization (TDR) value</measure>
    <time_frame>20 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of individuals with QTc increase by 50 ms and TDR increase by 25 ms</measure>
    <time_frame>20 min</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Cardiac Repolarization</condition>
  <arm_group>
    <arm_group_label>Droperidol 0.625 mg intravenously</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Droperidol 1.25 mg intravenously</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ondansetron 8 mg intravenously</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xomolix 0.625 mg intravenously</intervention_name>
    <description>intravenous administration of 0.625 mg droperidol</description>
    <arm_group_label>Droperidol 0.625 mg intravenously</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xomolix 1.25 mg</intervention_name>
    <description>intravenous administration of 1.25 mg droperidol</description>
    <arm_group_label>Droperidol 1.25 mg intravenously</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zofran 8 mg</intervention_name>
    <description>intravenous administration of 8 mg ondansetron</description>
    <arm_group_label>Ondansetron 8 mg intravenously</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18-60 years

          -  sex: males

          -  ASA score I or II

        Exclusion Criteria:

          -  treatment with drugs influencing cardiac repolarization

          -  coronary artery disease

          -  heart insufficiency NYHA&gt;1

          -  serum electrolyte disturbances

          -  hypersensitivity to droperidol and/or ondansetron
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical University of Gdansk</name>
      <address>
        <city>Gdansk</city>
        <zip>80-214</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2013</study_first_submitted>
  <study_first_submitted_qc>March 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2013</study_first_posted>
  <last_update_submitted>August 5, 2013</last_update_submitted>
  <last_update_submitted_qc>August 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Gdansk</investigator_affiliation>
    <investigator_full_name>Radoslaw Owczuk</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Droperidol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

